COMMUNIQUÉS West-GlobeNewswire

Helsinn announces European Commission approval of AKYNZEO® Oral Suspension
18/02/2026
Lugano, Switzerland – February 18th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, today announced that the European Commission [...]
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
18/02/2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 3, 2026 NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease [...]
BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care
18/02/2026
BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today [...]
Medicenna Therapeutics Announces Participation in Upcoming Conferences
18/02/2026
TORONTO and HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
18/02/2026
CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact [...]
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
18/02/2026
NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it [...]
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
18/02/2026
MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a [...]
Advanced Biomed Inc. Announces 1 for 20 Share Consolidation
18/02/2026
Tainan City, Taiwan, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company” or “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical [...]
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
18/02/2026
BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial [...]
Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada
18/02/2026
COPENHAGEN, Denmark, February 18, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced a new order valued at USD 22.5 million from the Public Health Agency of Canada (PHAC) for the Company’s mpox and smallpox vaccine [...]
NewBiologix Announces Publication of Breakthrough HEK293 Cell Line Optimized for High-Quality rAAV Production
18/02/2026
Paper reports two-fold higher full-to-empty rAAV ratio using NBX1P01 compared to a leading commercial HEK293 cell line LAUSANNE, Switzerland, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NewBiologix S.A., a biotechnology company [...]
Defeating the "Cold Chain" Barrier: Bio Usawa and Nanoly Bioscience Announce Strategic $500 Million Licensing Agreement for Breakthrough DynaShield™ Technology
18/02/2026
SAN FRANCISCO and LOS ANGELES and KIGALI, Rwanda, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bio Usawa, a leader in expanding global access to biopharmaceuticals, and Nanoly Bioscience, a pioneer in chemical stabilization, today [...]
Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830
18/02/2026
Press release – No. 4 / 2026 Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 Single doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose- [...]
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
18/02/2026
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types 1 Remibrutinib, a highly selective oral BTK inhibitor, was well-tolerated and [...]
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
18/02/2026
MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies [...]
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
17/02/2026
–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, [...]
Portsmouth Square, Inc. Reports Second Quarter Fiscal 2026 Results; Hotel Performance Improves Year-Over-Year as Market Stabilization Continues
17/02/2026
Los Angeles, California, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Portsmouth Square, Inc. (the “Company” or “Portsmouth”) today announced financial results for the fiscal second quarter ended December 31, 2025. Portsmouth’s [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
17/02/2026
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 17 févr. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
17/02/2026
Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first line (1L) metastatic [...]

Pages